Asset Acquisition, Assets Acquired

No definition available.

Name:	gild_AssetAcquisitionAssetsAcquired
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Asset Acquisition, Liabilities Assumed

+ References

No definition available.

+ Details

Name:	gild_AssetAcquisitionLiabilitiesAssumed
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Liabilities Assumed, Payment

+ References

No definition available.

+ Details

Name:	gild_AssetAcquisitionLiabilitiesAssumedPayment
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	gild_PaymentsForAssetAcquisitions
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments To Extinguish Future Royalty Obligation

+ References

No definition available.

+ Details

Name:	gild_PaymentsToExtinguishFutureRoyaltyObligation
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential Future Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_CymaBayMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gild_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_XinTheraIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gild_TmunityAndUniversityOfPennsylvaniaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_MiroBioLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS - Additional Information (Details) - USD ($) $ in Millions			1 Months Ended				12 Months Ended
	Feb. 22, 2023	Sep. 20, 2022	Jul. 31, 2024	Mar. 31, 2024	Oct. 31, 2023	May 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses							$ 4,663	$ 1,155	$ 944
Stock-based compensation expense							969	796	645
Research and development expenses
Business Combination, Separately Recognized Transactions [Line Items]
Stock-based compensation expense							458	377	285
Selling, general and administrative expenses
Business Combination, Separately Recognized Transactions [Line Items]
Stock-based compensation expense							450	361	313
CymaBay
Business Combination, Separately Recognized Transactions [Line Items]
Asset acquisition consideration				$ 3,900
Acquired in-process research and development expenses							3,800
Stock-based compensation expense							133
Asset acquisition, assets acquired							333
Asset acquisition, liabilities assumed							228
Liability payments							209
CymaBay \| Research and development expenses
Business Combination, Separately Recognized Transactions [Line Items]
Stock-based compensation expense							67
CymaBay \| Selling, general and administrative expenses
Business Combination, Separately Recognized Transactions [Line Items]
Stock-based compensation expense							67
CymaBay \| Janssen Pharmaceutica NV
Business Combination, Separately Recognized Transactions [Line Items]
Payment to extinguish a future royalty obligation			$ 320
XinThera, Inc
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses					$ 50			170
Cash consideration						$ 200
Maximum potential future milestone payments						$ 760
Tmunity Therapeutics
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses								244
Cash consideration	$ 300
Tmunity Therapeutics \| Tmunity And University Of Pennsylvania
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses							47	$ 25
Maximum potential future milestone payments							$ 1,000
MiroBio Ltd.
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses									$ 389
Cash consideration		$ 414